AstraZeneca's Portfolio Diversity Bodes Well — Market Talk
AstraZeneca has a robust and diverse portfolio, with strong opportunities in its pipeline, analysts at Berenberg say in a note. The pharmaceutical company is on track to deliver 13% return on research and development investment for its current pipeline cohort, they say. There have been some failure…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.